-
Obstetrician hands in a pregnant woman
-
Obstructive sleep apnea and other vascular risk factors’ impact on Non-motor Symptoms in Parkinson’s Disease
-
Olfactory dysfunction in incidental Lewy body disease and Parkinson’s disease: An update
-
Oligodendroglial-derived exosomes as mediators of α-synuclein pathology in MSA-like models
-
ON/OFF Blood Pressure Fluctuation in Parkinson’s Disease
-
OnabotulinumtoxinA treatment in patients with upper limb and lower limb spasticity from the ASPIRE study
-
Onset of complications in patients with Parkinson disease in Brazilian Amazon: cohort study.
-
Open-Source Tremor Tracking for MR-guided Focused Ultrasound (MRgFUS): An Objective Approach for Monitoring Treatments
-
Opicapone Analysis of Health Economic Costs in Clinical Practice in Parkinson’s Disease UK Patients with Motor Fluctuations: Findings from the OPTIPARK Study
-
Opicapone in clinical practice in Parkinson’s disease patients with motor fluctuations and complications of therapy at baseline: findings from the OPTIPARK study
-
Opicapone in Clinical Practice in Parkinson’s Disease UK Patients with Motor Fluctuations: Findings from the OPTIPARK Study
-
Opicapone in Parkinson’s Disease German Patients with Motor Fluctuations: Findings from the OPTIPARK Study
-
Opicapone in Parkinson’s disease patients with early/simple motor fluctuations: real-world Spanish data
-
OPTI-ON: A Longitudinal Real-World Study of Opicapone in Patients with Parkinson’s Disease and Motor Fluctuations
-
OPTIMIPARK Questionnaire:a tool to optimize treatment in Parkinson´s disease.
-
Optimizing an Electronic Health Records (EHR)-based Algorithm for Parkinson’s Disease Case Ascertainment
-
Outcome of Movement Disorders affected by Covid-19: case series from a single Movement Disorders Unit
-
Outcomes of a Peer Reviewing Education and Mentoring Program
-
Outcomes of Gene therapy and Subsequent Deep Brain Stimulation for Parkinson’s Disease
-
Overcoming clinical research challenges during a pandemic: selection and implementation of digital phenotyping solutions in a natural history study of G2019S LRRK2 Parkinson’s disease.
-
Overview of the population of patients with advanced Parkinson’s disease (aPD) initiating therapy with levodopa-carbidopa intestinal gel (LCIG): POMPE-PARK study on French health insurance data (2013-2017)
MDS Virtual Congress 2021
September 17-22, 2021. Virtual Congress. www.mdscongress.org